Table of Contents 
Chemotherapy Research and Practice
Volume 2011, Article ID 878912, 8 pages
http://dx.doi.org/10.1155/2011/878912
Review Article

New Agents Targeting Angiogenesis in Glioblastoma

Eleni Timotheadou

Department of Medical Oncology, Aristotle University of Thessaloniki School of Medicine and General Hospital “Papageorgiou”, 54303 Thessaloniki, Greece

Received 30 April 2011; Revised 22 July 2011; Accepted 23 August 2011

Academic Editor: Andreas F. Hottinger

Copyright © 2011 Eleni Timotheadou. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. Stupp, W. P. Mason, M. J. van den Bent et al., “Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma,” The New England Journal of Medicine, vol. 352, no. 10, pp. 987–996, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  2. K. H. Plate, G. Breier, H. A. Weich, and W. Risau, “Vascular endothelial growth factor is a potential tumour angiogenssis factor in human gliomas in vivo,” Nature, vol. 359, no. 6398, pp. 845–848, 1992. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  3. K. Samoto, K. Ikezaki, M. Ono et al., “Expression of vascular endothelial growth factor and its possible relation with neovascularization in human brain tumors,” Cancer Research, vol. 55, no. 5, pp. 1189–1193, 1995. View at Google Scholar · View at Scopus
  4. B. Kaur, F. W. Khwaja, E. A. Severson, S. L. Matheny, D. J. Brat, and E. G. Van Meir, “Hypoxia and the hypoxia-inducible-factor pathway in glioma growth and angiogenesis,” Neuro-Oncology, vol. 7, no. 2, pp. 134–153, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  5. D. G. Duda, K. S. Cohen, S. V. Kozin et al., “Evidence for incorporation of bone marrow-derived endothelial cells into perfused blood vessels in tumors,” Blood, vol. 107, no. 7, pp. 2774–2776, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  6. C. Murdoch, M. Muthana, S. B. Coffelt, and C. E. Lewis, “The role of myeloid cells in the promotion of tumour angiogenesis,” Nature Reviews Cancer, vol. 8, no. 8, pp. 618–631, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  7. R. K. Jain, R. T. Tong, and L. L. Munn, “Effect of vascular normalization by antiangiogenic therapy on interstitial hypertension, peritumor edema, and lymphatic metastasis: insights from a mathematical model,” Cancer Research, vol. 67, no. 6, pp. 2729–2735, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  8. K. Lamszus, O. Heese, and M. Westphal, “Angiogenesis-related growth factors in brain tumors,” Cancer Treatment and Research, vol. 117, pp. 169–190, 2004. View at Google Scholar · View at Scopus
  9. O. Kargiotis, J. S. Rao, and A. P. Kyritsis, “Mechanisms of angiogenesis in gliomas,” Journal of Neuro-Oncology, vol. 78, no. 3, pp. 281–293, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  10. R. K. Jain, E. di Tomaso, D. G. Duda, J. S. Loeffler, A. G. Sorensen, and T. T. Batchelor, “Angiogenesis in brain tumours,” Nature Reviews Neuroscience, vol. 8, no. 8, pp. 610–622, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  11. D. Wang, J. C. Anderson, and C. L. Gladson, “The role of the extracellular matrix in angiogenesis in malignant glioma tumors,” Brain Pathology, vol. 15, no. 4, pp. 318–326, 2005. View at Google Scholar · View at Scopus
  12. S. S. Lakka, C. S. Gondi, and J. S. Rao, “Proteases and glioma angiogenesis,” Brain Pathology, vol. 15, no. 4, pp. 327–341, 2005. View at Google Scholar · View at Scopus
  13. C. J. Shawber and J. Kitajewski, “Notch function in the vasculature: insights from zebrafish, mouse and man,” BioEssays, vol. 26, no. 3, pp. 225–234, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  14. C. K. Williams, J. L. Li, M. Murga, A. L. Harris, and G. Tosato, “Up-regulation of the Notch ligand Delta-like 4 inhibits VEGF-induced endothelial cell function,” Blood, vol. 107, no. 3, pp. 931–939, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  15. C. G. Willett, Y. Boucher, E. di Tomaso et al., “Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer,” Nature Medicine, vol. 10, no. 2, pp. 145–147, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  16. R. K. Jain, “Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy,” Science, vol. 307, no. 5706, pp. 58–62, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  17. C. G. Willett, Y. Boucher, D. G. Duda et al., “Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients,” Journal of Clinical Oncology, vol. 23, no. 31, pp. 8136–8139, 2005. View at Publisher · View at Google Scholar · View at PubMed
  18. I. Fischer, C. H. Cunliffe, R. J. Bollo et al., “High-grade glioma before and after treatment with radiation and Avastin: initial observations,” Neuro-Oncology, vol. 10, no. 5, pp. 700–708, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  19. T. T. Batchelor, A. G. Sorensen, E. di Tomaso et al., “AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients,” Cancer Cell, vol. 11, no. 1, pp. 83–95, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  20. J. J. Vredenburgh, A. Desjardins, J. E. Herndon II et al., “Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma,” Clinical Cancer Research, vol. 13, no. 4, pp. 1253–1259, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  21. T. N. Kreisl, L. Kim, K. Moore et al., “Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma,” Journal of Clinical Oncology, vol. 27, no. 5, pp. 740–745, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  22. A. D. Norden, G. S. Young, K. Setayesh et al., “Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence,” Neurology, vol. 70, no. 10, pp. 779–787, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  23. M. D. Prados, K. Lamborn, W. K. A. Yung et al., “A phase 2 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study,” Neuro-Oncology, vol. 8, no. 2, pp. 189–193, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  24. T. T. Batchelor, M. R. Gilbert, J. G. Supko et al., “Phase 2 study of weekly irinotecan in adults with recurrent malignant glioma: final report of NABTT 97-11,” Neuro-Oncology, vol. 6, no. 1, pp. 21–27, 2004. View at Publisher · View at Google Scholar · View at Scopus
  25. H. S. Friedman, M. D. Prados, P. Y. Wen et al., “Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma,” Journal of Clinical Oncology, vol. 27, no. 28, pp. 4733–4740, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  26. A. Lai, A. Tran, P. L. Nghiemphu et al., “Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme,” Journal of Clinical Oncology, vol. 29, no. 2, pp. 142–148, 2011. View at Publisher · View at Google Scholar · View at PubMed
  27. S. R. Wedge, J. Kendrew, L. F. Hennequin et al., “AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer,” Cancer Research, vol. 65, no. 10, pp. 4389–4400, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  28. T. T. Batchelor, D. G. Duda, E. di Tomaso et al., “Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma,” Journal of Clinical Oncology, vol. 28, no. 17, pp. 2817–2823, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  29. T. Batchelor, P. Mulholland, B. Neyns et al., “The efficacy of cediranib as monotherapy and in combination with lomustine compared to lomustine alone in patients with recurrent glioblastoma: a phase III randomized study,” Neuro-Oncology, vol. 12, supplement 4, pp. iv69–iv78, 2010. View at Google Scholar
  30. http://clinicaltrials.gov/ct2/results?term=cediranib+in+glioma.
  31. S. L. Goodman, G. Hölzemann, G. A. G. Sulyok, and H. Kessler, “Nanomolar small molecule inhibitors for alpha(V) beta(6), alpha(V)beta(5), and alpha(V)beta(3) integrins,” Journal of Medicinal Chemistry, vol. 45, no. 5, pp. 1045–1051, 2002. View at Publisher · View at Google Scholar · View at Scopus
  32. G. D. Maurer, I. Tritschler, B. Adams et al., “Cilengitide modulates attachment and viability of human glioma cells, but not sensitivity to irradiation or temozolomide in vitro,” Neuro-Oncology, vol. 11, no. 6, pp. 747–756, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  33. O. Schnell, B. Krebs, E. Wagner et al., “Expression of integrin alpha(V)beta(3) in gliomas correlates with tumor grade and is not restricted to tumor vasculature,” Brain Pathology, vol. 18, no. 3, pp. 378–386, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  34. L. B. Nabors, T. Mikkelsen, S. S. Rosenfeld et al., “Phase I and correlative biology study of cilengitide in patients with recurrent malignant glioma,” Journal of Clinical Oncology, vol. 25, no. 13, pp. 1651–1657, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  35. D. A. Reardon, K. L. Fink, T. Mikkelsen et al., “Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme,” Journal of Clinical Oncology, vol. 26, no. 34, pp. 5610–5617, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  36. T. Mikkelsen, C. Brodie, S. Finniss et al., “Radiation sensitization of glioblastoma by cilengitide has unanticipated schedule-dependency,” International Journal of Cancer, vol. 124, no. 11, pp. 2719–2727, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  37. R. Stupp, M. E. Hegi, B. Neyns et al., “Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma,” Journal of Clinical Oncology, vol. 28, no. 16, pp. 2712–2718, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  38. R. Stupp, M. J. Van Den Bent, S. C. Erridge et al., “Cilengitide in newly diagnosed glioblastoma with MGMT promoter methylation: protocol of a multicenter, randomized, open-label, controlled phase III trial (CENTRIC),” Journal of Clinical Oncology, vol. 28, no. 15 supplement, abstract no. TPS152, 2010. View at Google Scholar
  39. M. Khasraw, S. A. McCowatt, Z. Kerestes et al., “Radiotherapy (RT), temozolomide (TMZ), procarbazine (PCB), and the integrin inhibitor cilengitide in patients with glioblastoma (GBM) without methylation of the MGMT gene promoter (ExCentric),” Journal of Clinical Oncology, vol. 29, no. 15 supplement, abstract no. TPS133, 2011. View at Google Scholar
  40. http://clinicaltrials.gov/ct2/results?term=cilengitide+in+glioma.
  41. A. K. Koutras, D. Krikelis, N. Alexandrou, I. Starakis, and H. P. Kalofonos, “Brain metastasis in renal cell cancer responding to sunitinib,” Anticancer Research, vol. 27, no. 6, pp. 4255–4257, 2007. View at Google Scholar · View at Scopus
  42. M. Chahal, Y. Xu, D. Lesniak et al., “MGMT modulates glioblastoma angiogenesis and response to the tyrosine kinase inhibitor sunitinib,” Neuro-Oncology, vol. 12, no. 8, pp. 822–833, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  43. Q. Zhou, P. Guo, and J. M. Gallo, “Impact of angiogenesis inhibition by sunitinib on tumor distribution of temozolomide,” Clinical Cancer Research, vol. 14, no. 5, pp. 1540–1549, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  44. B. Neyns, J. Sadones, C. Chaskis et al., “Phase II study of sunitinib malate in patients with recurrent high-grade glioma,” Journal of Neuro-Oncology, vol. 103, no. 3, pp. 491–501, 2011. View at Publisher · View at Google Scholar · View at PubMed
  45. D. A. Reardon, J. J. Vredenburgh, A. Coan et al., “Phase I study of sunitinib and irinotecan for patients with recurrent malignant glioma,” Journal of Neuro-Oncology. In press. View at Publisher · View at Google Scholar · View at PubMed
  46. http://clinicaltrials.gov/ct2/results?term=sunitinib+in+glioblastoma.
  47. F. Yang, C. Brown, R. Buettner et al., “Sorafenib induces growth arrest and apoptosis of human glioblastoma cells through the dephosphorylation of signal transducers and activators of transcription 3,” Molecular Cancer Therapeutics, vol. 9, no. 4, pp. 953–962, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  48. J. D. Hainsworth, T. Ervin, E. Friedman et al., “Concurrent radiotherapy and temozolomide followed by temozolomide and sorafenib in the first-line treatment of patients with glioblastoma multiforme,” Cancer, vol. 116, no. 15, pp. 3663–3669, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  49. http://clinicaltrials.gov/ct2/results?term=sorafenib+in+glioblastoma.
  50. P. R. Wachsberger, Y. R. Lawrence, Y. Liu, B. Daroczi, X. Xu, and A. P. Dicker, “Epidermal Growth Factor Receptor Expression Modulates Antitumor Efficacy of Vandetanib or Cediranib Combined with Radiotherapy in Human Glioblastoma Xenografts,” International Journal of Radiation Oncology, Biology, Physics. In press. View at Publisher · View at Google Scholar · View at PubMed
  51. V. Damiano, D. Melisi, C. Bianco et al., “Cooperative antitumor effect of multitargeted kinase inhibitor ZD6474 and ionizing radiation in glioblastoma,” Clinical Cancer Research, vol. 11, no. 15, pp. 5639–5644, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  52. A. Claes, P. Wesseling, J. Jeuken, C. Maass, A. Heerschap, and W. P. J. Leenders, “Antiangiogenic compounds interfere with chemotherapy of brain tumors due to vessel normalization,” Molecular Cancer Therapeutics, vol. 7, no. 1, pp. 71–78, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  53. J. Drappatz, A. D. Norden, E. T. Wong et al., “Phase I study of vandetanib with radiotherapy and temozolomide for newly diagnosed glioblastoma,” International Journal of Radiation Oncology Biology Physics, vol. 78, no. 1, pp. 85–90, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  54. P. Bornstein, “Diversity of function is inherent in matricellular proteins: an appraisal of thrombospondin 1,” Journal of Cell Biology, vol. 130, no. 3, pp. 503–506, 1995. View at Google Scholar · View at Scopus
  55. D. J. Good, P. J. Polverini, F. Rastinejad et al., “A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin,” Proceedings of the National Academy of Sciences of the United States of America, vol. 87, no. 17, pp. 6624–6628, 1990. View at Google Scholar · View at Scopus
  56. G. Taraboletti, D. Roberts, L. A. Liotta, and R. Giavazzi, “Platelet thrombospondin modulates endothelial cell adhesion, motility, and growth: a potential angiogenesis regulatory factor,” Journal of Cell Biology, vol. 111, no. 2, pp. 765–772, 1990. View at Publisher · View at Google Scholar · View at Scopus
  57. N. H. Guo, H. C. Krutzsch, J. K. Inman, and D. D. Roberts, “Thrombospondin 1 and type I repeat peptides of thrombospondin 1 specifically induce apoptosis of endothelial cells,” Cancer Research, vol. 57, no. 9, pp. 1735–1742, 1997. View at Google Scholar · View at Scopus
  58. D. W. Dawson, S. F. A. Pearce, R. Zhong, R. L. Silverstein, W. A. Frazier, and N. P. Bouck, “CD36 mediates the in vitro inhibitory effects of thrombospondin-1 on endothelial cells,” Journal of Cell Biology, vol. 138, no. 3, pp. 707–717, 1997. View at Publisher · View at Google Scholar · View at Scopus
  59. M. Tenan, G. Fulci, M. Albertoni et al., “Thrombospondin-1 is downregulated by anoxia and suppresses tumorigenicity of human glioblastoma cells,” Journal of Experimental Medicine, vol. 191, no. 10, pp. 1789–1798, 2000. View at Publisher · View at Google Scholar · View at Scopus
  60. S. Filleur, O. V. Volpert, A. Degeorges et al., “In vivo mechanisms by which tumors producing thrombospondin 1 bypass its inhibitory effects,” Genes and Development, vol. 15, no. 11, pp. 1373–1382, 2001. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  61. L. B. Nabors, J. B. Fiveash, J. M. Markert et al., “A phase 1 trial of ABT-510 concurrent with standard chemoradiation for patients with newly diagnosed glioblastoma,” Archives of Neurology, vol. 67, no. 3, pp. 313–319, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  62. J. F. De Groot, M. Prados, T. Urquhart et al., “A phase II study of XL184 in patients (pts) with progressive glioblastoma multiforme (GBM) in first or second relapse,” Journal of Clinical Oncology, vol. 27, no. 15 supplement, abstract no. 2047, 2009. View at Google Scholar
  63. P. Y. Wen, M. Prados, D. Schiff et al., “Phase II study of XL184 (BMS 907351), an inhibitor of MET, VEGFR2, and RET, in patients (pts) with progressive glioblastoma (GB),” Journal of Clinical Oncology, vol. 28, no. 15 supplement, abstract no. 2006, 2010. View at Google Scholar
  64. http://www.clinicaltrials.gov/ct2/results?term=XL184+in+glioma.
  65. J. Holash, S. Davis, N. Papadopoulos et al., “VEGF-Trap: a VEGF blocker with potent antitumor effects,” Proceedings of the National Academy of Sciences of the United States of America, vol. 99, no. 17, pp. 11393–11398, 2002. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  66. E. S. Kim, A. Serur, J. Huang et al., “Potent VEGF blockade causes regression of coopted vessels in a model of neuroblastoma,” Proceedings of the National Academy of Sciences of the United States of America, vol. 99, no. 17, pp. 11399–11404, 2002. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  67. G. J. Riely and V. A. Miller, “Vascular endothelial growth factor trap in non small cell lung cancer,” Clinical Cancer Research, vol. 13, no. 15, pp. s4623–s4627, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  68. P. R. Wachsberger, R. Burd, C. Cardi et al., “VEGF trap in combination with radiotherapy improves tumor control in u87 glioblastoma,” International Journal of Radiation Oncology Biology Physics, vol. 67, no. 5, pp. 1526–1537, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  69. C. Gomez-Manzano, J. Holash, J. Fueyo et al., “VEGF Trap induces antiglioma effect at different stages of disease,” Neuro-Oncology, vol. 10, no. 6, pp. 940–945, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  70. http://www.clinicaltrials.gov/ct2/results?term=Aflibercept+in+glioma.
  71. M. M. Schittenhelm, K. M. Kampa, K. W. H. Yee, and M. C. Heinrich, “The FLT3 inhibitor tandutinib (formerly MLN518) has sequence-independent synergistic effects with cytarabine and daunorubicin,” Cell Cycle, vol. 8, no. 16, pp. 2621–2630, 2009. View at Google Scholar · View at Scopus
  72. http://www.clinicaltrials.gov/ct2/results?term=tandutinib+in+glioma.